FIG 3.

CDK2 inhibition affects activation-induced HIV-1 reactivation. If a reduction in CDK2 activity renders T cells unresponsive, we would expect CDK2 inhibitors to reduce the ability of otherwise potent agents, such as PMA, to trigger HIV-1 reactivation. We thus tested the concentration-dependent effects of a series of specific CDK2 inhibitors in preventing PMA-induced HIV-1 reactivation in CA5 T cells. The CDK2 inhibitors used were roscovitine (A), purvalanol (B), CDK2 inhibitor III (CDK2i III) (C), and kenpaullone (D). Cells were pretreated for 2 h with the indicated concentration of the respective CDK2 inhibitor, followed by stimulation with a high dose of PMA (10 nM). HIV-1 reactivation levels were determined as the percentage of GFP-positive cells 48 h post-PMA addition. Data for at least 3 independent experiments are presented.